Free tool
FAERS Monitor: Aleve Pm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205352 or its brand name (Aleve Pm, Diphenhydramine Hydrochloride, Naproxen Sodium). Reports on generic versions are filed under their own applications.
Reports
2,033
Serious
189
9% of reports
Hospitalization
63
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use issue466
- drug ineffective461
- insomnia185
- medication error133
- product use in unapproved indication113
- somnolence113
- therapeutic response unexpected103
- incorrect drug administration duration101
- incorrect dose administered73
- expired product administered61
- drug ineffective for unapproved indication60
- feeling abnormal59
- underdose59
- fatigue45
- headache45
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2014 | 184 |
| 2015 | 521 |
| 2016 | 358 |
| 2017 | 225 |
| 2018 | 236 |
| 2019 | 246 |
| 2020 | 87 |
| 2021 | 54 |
| 2022 | 40 |
| 2023 | 21 |
| 2024 | 30 |
| 2025 | 15 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,126 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| incorrect drug administration durationSignal | 101 | 37.3 | 30.8 | 3,522 |
| product use issueSignal | 466 | 25.7 | 23.7 | 11,116 |
| medication errorSignal | 133 | 24.8 | 21.0 | 3,016 |
| therapeutic response unexpectedSignal | 103 | 23.8 | 19.7 | 2,227 |
| expired product administeredSignal | 61 | 19.0 | 14.9 | 1,023 |
| drug ineffective for unapproved indicationSignal | 60 | 11.3 | 8.8 | 555 |
| underdoseSignal | 59 | 8.4 | 6.5 | 376 |
| insomniaSignal | 185 | 7.2 | 6.3 | 992 |
| somnolenceSignal | 113 | 5.8 | 4.9 | 449 |
| product use in unapproved indicationSignal | 113 | 4.7 | 3.9 | 331 |
| drug ineffectiveSignal | 461 | 3.6 | 3.3 | 929 |
| incorrect dose administeredSignal | 73 | 3.3 | 2.6 | 117 |
| feeling abnormalSignal | 59 | 2.5 | 2.0 | 55 |
| headache | 45 | 0.7 | 0.6 | 4 |
| fatigue | 45 | 0.6 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.